Coronavirus Notebook: New EU Body To Advise On Future Pandemic Actions, Valneva Awaits EMA Verdict On Vaccine Candidate
French health tech firm NOVA has produced a model for assessing the impact of non-pharmaceutical COVID-19 interventions on clinical trials of respiratory tract drugs, and Moderna’s Spikevax has been OKd for younger children in Great Britain.
You may also be interested in...
Coronavirus Notebook: Global COVID-19 Summit To Press For More Funding For Vaccines & Treatments, WHO Calls For End To IP Waiver ‘Stalemate’
CEPI has announced funding for a “variant-proof” vaccine being developed by a multidisciplinary consortium. The European Medicines Agency's new committee on drug shortages in health crises has held its first meeting, and the European Parliament’s new COVID-19 committee will quiz the health commissioner on the EU’s vaccines strategy and response to the pandemic.
As work continues on vaccines adapted to tackle variants of SARS-CoV-2, the EU regulator says the decision-making on such products should take place at a global level.
The MHRA has become the first regulatory agency worldwide to grant a marketing authorization for the inactivated whole virus COVID-19 vaccine, VLA2001.